KLRS — Kalaris Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1754068 ·
Last close
$1.43
Market Cap
$34.04M
52W High
$11.88
52W Low
$1.33
ADV30
88,929
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -11,811,000 | -11,026,000 | 89,003,000 | 47,384,000 | 41,601,000 |
| Jun 2026 | 0 | — | -12,386,000 | -11,515,000 | 99,539,000 | 43,173,000 | 41,867,000 |
| Mar 2026 | 0 | — | -11,833,000 | -10,856,000 | 109,805,000 | 34,427,000 | 41,248,000 |
| Dec 2025 | 0 | — | -10,801,000 | -9,998,000 | 121,736,000 | 98,054,000 | 42,922,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-40,239,000
Investing CF
$-357,000
Financing CF
$45,593,000
CapEx
$-17,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.04
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-193,396,000
Inventory
—
Receivables
—
ST Investments
$35,472,000
EBIT TTM
$-43,395,000
Pretax Income TTM
$-43,395,000
Interest Exp TTM
$0
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -46,152,000 | -43,438,000 | 121,736,000 | 42,922,000 | 78,814,000 | -38,370,000 |
| Dec 2024 | 0 | -51,732,000 | -69,167,000 | 6,162,000 | 102,778,000 | -96,616,000 | -20,670,000 |
| Dec 2023 | 0 | -13,464,000 | -14,699,000 | 3,333,000 | 48,350,000 | -45,017,000 | -14,132,000 |
| Dec 2022 | 0 | -14,006,000 | -15,485,000 | 3,899,000 | 34,171,000 | -30,272,000 | -9,779,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-44,263,000
OpCashFlow TTM
—
Assets (Latest)
$99,539,000
Forward EPS
$-1.70
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GNTA | Genenta Science S.p.A. | $33.03M | $0.69 | — |
| CVM | CEL SCI CORP | $32.54M | $1.85 | — |
| BKHA | Black Hawk Acquisition Corp | $35.93M | $8.65 | — |
| TIL | Instil Bio, Inc. | $36.62M | $5.40 | — |
| CRBU | Caribou Biosciences, Inc. | $36.81M | $0.34 | — |
News headlines (Yahoo Finance, 1h cache)
Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-10 12:30 · Yahoo
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-31 12:00 · Yahoo
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
2026-07-20 12:00 · Yahoo
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
2026-07-17 11:00 · Yahoo
Kalaris Appoints Laurie Keating to Board of Directors
2026-07-06 20:05 · Yahoo
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
2026-06-23 12:00 · Yahoo
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 12:00 · Yahoo
Kalaris to Present at Clinical Trials at the Summit 2026
2026-06-12 12:00 · Yahoo
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-11 12:00 · Yahoo
Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
2026-07-14 18:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.